Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Wellspan Health

Neither a doctor nor a teaching hospital

Research payments

$2,816,685

742 payments

Through program year 2025, Wellspan Health is reported as receiving $2,816,685 in research payments, across 742 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $658,170 130
2024 Research $581,101 156
2023 Research $336,619 99
2022 Research $379,988 144
2021 Research $292,901 94
2020 Research $239,737 60
2019 Research $328,169 59

Breakdown

Who paid Research payments · program years 2019–2025
  1. Boston Scientific Corporation $864,792 348 payments
  2. Eli Lilly and Company $480,761 19 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $231,567 61 payments
  4. E.R. Squibb & Sons, L.L.C. $185,763 6 payments
  5. Abbott Laboratories $130,211 69 payments
  6. Shockwave Medical, Inc $110,109 24 payments
  7. Biosense Webster, Inc. $97,984 9 payments
  8. Array BioPharma Inc. $69,512 21 payments
  9. AstraZeneca Pharmaceuticals LP $67,399 11 payments
  10. AstraZeneca UK Limited $52,395 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. Acurate Ide $244,844 56 payments
  2. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $225,655 2 payments
  3. A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer $149,739 9 payments
  4. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subjects With Lennox-Gastaut Syndrome (LGS) $147,095 27 payments
  5. A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Response-Adaptive Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Aspirin and C $108,464 1 payment
  6. Option $103,061 61 payments
  7. Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation with the BWI PFA Pulsed Field Ablation (PFA) System with OMNYPULSE Catheter $97,984 9 payments
  8. A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome $84,472 34 payments
  9. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $70,324 2 payments
  10. Champion Af $61,717 21 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record